Oculus Innovative Sciences (Petaluma, Calif) will launch its Dermacyn® wound treatment product in China by sending samples of the product to hospitals in 10 China provinces. Dermacyn Wound Care with Microcyn Technology is a nonirritating, nonsensitizing, no-rinse dermal wound care treatment for moistening absorbent wound dressings, debriding, and cleaning acute and chronic dermal lesions. Microcyn’s super oxygenated water keeps the wound moist and is effective against bacteria, viruses, mold and spores, including MRSA-resistant bacteria. One of the product’s main target markets is diabetic foot ulcers.

Sinopharm (Shanghai, China) regulates China’s distribution of the product; the State Food and Drug Administration approved it in March 2008 to treat acute and chronic wounds including ulcers, cuts, contusions and burns. The US allows the product to be used as a wound cleaning aid — a pivotal Phase III trial of the product as a treatment for infected wounds is just getting underway.

For more information, visit www.oculusis.com/us/.